Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Entero Therapeutics Inc ENTO

Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

NDAQ:ENTO - Post Discussion

Entero Therapeutics Inc > 3 shots on goal for 2021
View:
Post by askretka on Jan 15, 2021 8:24am

3 shots on goal for 2021

Recent letter to shareholders has all the info in it. CEO James Saperstein previously sold Tobira to Allergen for 1.7 Billion. " NEW YORK (TheStreet) --Shares ofTobira Therapeutics(TBRA)are skyrocketing on heavy trading volume on Tuesday morning by over 700% to $39.24, after it was announced the clinical-stage biopharmaceutical company will be acquired byAllergan(AGN) in a deal valued at up to $1.7 billion." Should have Results in Q1 and Q2 that could move the stock. CEO in letter to shareholders says we have a 3 shots at a billion dollar treatments in 2021. 1.People who get COVID-19 have GI problems. 2. People undergoing Chemotherapy who have GI problems and diarrhea have to get less than optimal dose or stop treatment 22 Billion dollar a year market. 3. Treatment for Cystic Fibrosis patients who have trouble with digestion
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities